Compare TG Therapeutics Inc (TGTX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Weibo Corp — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Weibo Corp trades at $6.67 (market cap $1.64B). The key difference: TG Therapeutics Inc is far larger — about 5.2× Weibo Corp's market cap, and Weibo Corp pays a 9.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WB | |
|---|---|---|
Market Cap | $8.53B | $1.64B |
Sector | Health | Media |
52-Week High | $59.06 | $12.83 |
52-Week Low | $26.94 | $6.63 |
Enterprise Value | $8.74B | $866.57M |
Dividend Yield | — | 9.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Weibo (WB) trades at $6.70, down 0.3% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. Fundamentally, the stock appears undervalued with a P/E of 5.53 and P/B of 0.41, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates.
The investment case balances deep value metrics against structural challenges. While the stock trades below book value and generates substantial cash flow, competitive pressures from Douyin and WeChat threaten long-term relevance. Analyst sentiment is divided with 41% buy ratings but 45% holds, reflecting uncertainty about growth visibility amid declining user metrics. The 8% dividend yield provides downside protection but may not offset fundamental erosion risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
